In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Therapy For Jerry's Kids

An Interview With the Muscular Dystrophy Association’s Sharon Hesterlee

Executive Summary

In her new role as executive vice president, chief research officer, Sharon Hesterlee brings industry bone fides and nonprofit experiences to bear on tomorrow’s neuromuscular treatments and cures. 

You may also be interested in...



Digital Therapeutics Have Arrived But Will Insurers Get On Board?

Will FDA-cleared prescription digital therapeutics be able to follow wellness, chronic disease and sleep disorder apps onto the formularies of major payers? For digital therapeutics companies investing in randomized controlled clinical trials, GMP manufacturing and FDA submissions for products, the current absence of public health insurance coverage is frustrating.

Exploring Latin America In The COVID-19 Era

Unique industry partnerships and new regulatory flexibility in Latin America may help to improve access to medicines, even as COVID-19 wreaks havoc in the region’s largest pharmaceutical market. Can biopharma’s bespoke solutions to market access barriers coalesce into a strategy capable of overcoming political, economic and COVID-19 related risks?   

Back To Business: Deal-Making On The Other Side Of COVID-19

COVID-19 has introduced new challenges (and more attorneys) into the biopharma deal-making environment, but experts say the fundamentals for deal activity point toward a rebound. Companies that adapt quickly to changes – in communication, due diligence and deal structure – will make successful connections in a time of social distancing.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1125347

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel